B
Beyond Air, Inc. (XAIR)
NCM – Real Time Price. Currency in USD
0.54
+0.02 (3.35%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.54
+0.02 (3.35%)
At close: May 12, 2026, 4:00 PM EDT
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
| Name | Position |
|---|---|
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board |
| Dr. John Jett Ph.D. | Head of Research & Clinical Development |
| Mr. Adam T. Newman | Corporate Secretary |
| Mr. Amir Avniel | Chief Executive Officer of NeuroNOS |
| Mr. Daniel J. Moorhead CPA | Chief Financial Officer |
| Mr. Denton Drewell | Principal Accounting Officer & Controller |
| Mr. Michael A. Gaul | Chief Operating Officer |
| Mr. Robert Scott Goodman | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | DEF 14A | formdef14a.htm |
| 2026-04-24 | PRE 14A | formpre14a.htm |
| 2026-04-15 | 8-K | form8-k.htm |
| 2026-04-10 | 8-K | form8-k.htm |
| 2026-04-01 | 8-K | form8-k.htm |
| 2026-02-13 | 8-K | form8-k.htm |
| 2026-02-13 | 10-Q | form10-q.htm |
| 2026-02-05 | CORRESP | filename1.htm |
| 2026-02-02 | 8-K | form8-k.htm |
| 2026-01-30 | S-3 | forms-3.htm |